Pei Xiang Xing

1.3k total citations
26 papers, 1.1k citations indexed

About

Pei Xiang Xing is a scholar working on Molecular Biology, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Pei Xiang Xing has authored 26 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 9 papers in Radiology, Nuclear Medicine and Imaging and 7 papers in Oncology. Recurrent topics in Pei Xiang Xing's work include Monoclonal and Polyclonal Antibodies Research (9 papers), Glycosylation and Glycoproteins Research (8 papers) and Peptidase Inhibition and Analysis (6 papers). Pei Xiang Xing is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (9 papers), Glycosylation and Glycoproteins Research (8 papers) and Peptidase Inhibition and Analysis (6 papers). Pei Xiang Xing collaborates with scholars based in Australia, United States and China. Pei Xiang Xing's co-authors include Xiu Feng Hu, Jun Yan, Jarosław Baran, Hong Feng, Daniel J. Allendorf, Nai‐Kong V. Cheung, Gary R. Ostroff, Gordon D. Ross, Richard Hansen and Tarik Möröy and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and The Journal of Immunology.

In The Last Decade

Pei Xiang Xing

25 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Pei Xiang Xing Australia 13 440 308 294 240 183 26 1.1k
Oliver Alabaster United States 20 323 0.7× 250 0.8× 338 1.1× 135 0.6× 100 0.5× 39 1.1k
Kamini Srivastava India 19 787 1.8× 150 0.5× 271 0.9× 223 0.9× 70 0.4× 45 1.3k
Jen Wei Chiao United States 20 760 1.7× 79 0.3× 205 0.7× 317 1.3× 119 0.7× 70 1.3k
A. Zimber Israel 18 701 1.6× 120 0.4× 461 1.6× 91 0.4× 73 0.4× 52 1.4k
Tatiana Efimova United States 19 786 1.8× 129 0.4× 225 0.8× 146 0.6× 53 0.3× 45 1.4k
Sara Baccarini Italy 11 406 0.9× 109 0.4× 491 1.7× 533 2.2× 145 0.8× 11 1.2k
Wenqi Jiang China 13 268 0.6× 246 0.8× 337 1.1× 426 1.8× 89 0.5× 52 1.0k
Qingdi Li United States 18 598 1.4× 162 0.5× 262 0.9× 141 0.6× 53 0.3× 35 1.1k
Uwe Trefzer Germany 19 618 1.4× 51 0.2× 338 1.1× 456 1.9× 219 1.2× 43 1.5k
Kulthida Vaeteewoottacharn Thailand 22 724 1.6× 187 0.6× 553 1.9× 285 1.2× 77 0.4× 90 1.7k

Countries citing papers authored by Pei Xiang Xing

Since Specialization
Citations

This map shows the geographic impact of Pei Xiang Xing's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pei Xiang Xing with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pei Xiang Xing more than expected).

Fields of papers citing papers by Pei Xiang Xing

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pei Xiang Xing. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pei Xiang Xing. The network helps show where Pei Xiang Xing may publish in the future.

Co-authorship network of co-authors of Pei Xiang Xing

This figure shows the co-authorship network connecting the top 25 collaborators of Pei Xiang Xing. A scholar is included among the top collaborators of Pei Xiang Xing based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pei Xiang Xing. Pei Xiang Xing is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Jie, Bruce E. Loveland, & Pei Xiang Xing. (2011). Anti-Pim-1 mAb inhibits activation and proliferation of T lymphocytes and prolongs mouse skin allograft survival. Cellular Immunology. 272(1). 87–93. 16 indexed citations
2.
Li, Jie, Xiu Feng Hu, Bruce E. Loveland, & Pei Xiang Xing. (2009). Pim-1 expression and monoclonal antibody targeting in human leukemia cell lines. Experimental Hematology. 37(11). 1284–1294. 19 indexed citations
3.
Hu, Xiu Feng, et al.. (2009). PIM-1–specific mAb suppresses human and mouse tumor growth by decreasing PIM-1 levels, reducing Akt phosphorylation, and activating apoptosis. Journal of Clinical Investigation. 119(2). 362–75. 83 indexed citations
4.
Hu, Xiu Feng, Eunice Yang, Jie Li, & Pei Xiang Xing. (2006). MUC1 cytoplasmic tail: a potential therapeutic target for ovarian carcinoma. Expert Review of Anticancer Therapy. 6(8). 1261–1271. 29 indexed citations
5.
Milland, Julie, et al.. (2006). The Molecular Basis for Galα(1,3)Gal Expression in Animals with a Deletion of the α1,3Galactosyltransferase Gene. The Journal of Immunology. 176(4). 2448–2454. 94 indexed citations
6.
Hu, Xiu Feng & Pei Xiang Xing. (2005). Cripto as a target for cancer immunotherapy. Expert Opinion on Therapeutic Targets. 9(2). 383–394. 11 indexed citations
7.
Bachmann, Malte, Christian Kosan, Pei Xiang Xing, et al.. (2005). The oncogenic serine/threonine kinase Pim-1 directly phosphorylates and activates the G2/M specific phosphatase Cdc25C. The International Journal of Biochemistry & Cell Biology. 38(3). 430–443. 103 indexed citations
8.
Feng, Hong, Jun Yan, Jarosław Baran, et al.. (2004). Mechanism by Which Orally Administered β-1,3-Glucans Enhance the Tumoricidal Activity of Antitumor Monoclonal Antibodies in Murine Tumor Models. The Journal of Immunology. 173(2). 797–806. 407 indexed citations
9.
Bachmann, Malte, Hanjo Hennemann, Pei Xiang Xing, Ingrid Hoffmann, & Tarik Möröy. (2004). The Oncogenic Serine/Threonine Kinase Pim-1 Phosphorylates and Inhibits the Activity of Cdc25C-associated Kinase 1 (C-TAK1). Journal of Biological Chemistry. 279(46). 48319–48328. 122 indexed citations
10.
Xing, Pei Xiang, Xiu Feng Hu, Geoffrey A. Pietersz, Howard L. Hosick, & Ian F. C. McKenzie. (2004). Cripto. Cancer Research. 64(11). 4018–4023. 52 indexed citations
11.
Hu, Xiu Feng & Pei Xiang Xing. (2003). Discovery and validation of new molecular targets for ovarian cancer.. PubMed. 5(6). 625–30. 9 indexed citations
12.
McKenzie, Ian F. C., et al.. (2003). CD46 protects pig islets from antibody but not cell‐mediated destruction in the mouse. Xenotransplantation. 10(6). 615–621. 9 indexed citations
13.
Xing, Pei Xiang. (2001). Anti-mucin monoclonal antibodies. Frontiers in bioscience. 6(1). d1284–d1284. 17 indexed citations
14.
Paul, Annick, Morvane Colin, Pei Xiang Xing, et al.. (2001). Glycoconjugate Metabolism in a Cystic Fibrosis Knockout Mouse Model. Molecular Genetics and Metabolism. 72(2). 122–131. 3 indexed citations
15.
Xing, Pei Xiang, et al.. (2001). Breast Cancer in Mice: Effect of Murine Muc-1 Immunization on Tumor Incidence in C3H/HeOuj Mice. Journal of Immunotherapy. 24(1). 10–18. 3 indexed citations
16.
Xing, Pei Xiang, et al.. (2000). Monoclonal Antibodies to Mucin VNTR Peptides. Humana Press eBooks. 125. 369–381. 5 indexed citations
17.
Xing, Pei Xiang, et al.. (1998). Mouse mucin 1 (MUC1) defined by monoclonal antibodies. International Journal of Cancer. 76(6). 875–883. 1 indexed citations
18.
Xing, Pei Xiang, et al.. (1998). Mouse mucin 1 (MUC1) defined by monoclonal antibodies. International Journal of Cancer. 76(6). 875–883. 18 indexed citations
19.
Hinoda, Yuji, Hirofumi Akashi, Fumio Itoh, et al.. (1998). Immunohistochemical detection of MUC2 mucin core protein in ulcerative colitis. Journal of Clinical Laboratory Analysis. 12(3). 150–153. 19 indexed citations
20.
Xing, Pei Xiang, et al.. (1996). A new approach to fecal occult blood testing based on the detection of haptoglobin. Cancer. 78(1). 48–56. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Oliver Alabaster Breakdown of academic impact, for papers by Kamini Srivastava Breakdown of academic impact, for papers by Jen Wei Chiao Breakdown of academic impact, for papers by A. Zimber Breakdown of academic impact, for papers by Tatiana Efimova Breakdown of academic impact, for papers by Sara Baccarini Breakdown of academic impact, for papers by Wenqi Jiang Breakdown of academic impact, for papers by Qingdi Li Breakdown of academic impact, for papers by Uwe Trefzer Breakdown of academic impact, for papers by Kulthida Vaeteewoottacharn
Rankless by CCL
2026